HEVA Reports Findings in Multiple Myeloma [Epidemiology of patients treated for multiple myeloma using a new algorithm in the French national health insurance database (SNDS): Results from the MYLORD study]: Oncology – Multiple Myeloma

2025 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- New research on Oncology - Multiple Myeloma is the subject of a report. According to news originating from Lyon, France, by NewsRx correspondents, research stated, “Management of multiple myeloma (MM) has evolved in the last decade, impacting epidemiology and creating the need for a revised algorithm for patient identification in the French National Health Insurance database (SNDS). The objective of the MYLORD study was to provide up-to-date epidemiological indicators for MM using the SNDS.”

Our news journalists obtained a quote from the research from HEVA, “Adults treated for MM between 2014 and 2020 were identified using hospital stays (ICD-10 code C90*) and/or Long-Term Disease status for MM (ICD-10 C90*) and treatment dispensation (MM specific treatments), or lenalidomide or thalidomide with 2 conditions: at least 2 Serum or Urine-Protein Electrophoresis performed within 4 months after the first drug dispensing and no hospital stays for other indications than MM. In 2020 in France, the number of new patients treated for MM was estimated at 5,608, corresponding to a world age-standardized incidence rate (ASIR) of 3.67 (3.55-3.78) per 100,000 patients. The total number of patients treated for MM was estimated at 33,675 corresponding to a world age-standardized prevalence rate (ASPR) of 22.34 (22.06-22.63) per 100,000 patients. The world ASIR slightly increased from 2014 to 2018, then slightly decreased until 2020. There is a regular increase of the ASPR every year in both men and women. The algorithm developed for the MYLORD study considerably improves the identification of patients treated for MM in the SNDS compared to the current French references and allows to generate robust epidemiological indicators.”

According to the news editors, the research concluded: “The stable incidence and the increase in prevalence from 2014 to 2020 reflect the improvement in therapeutic management over the years.”

For more information on this research see: Epidemiology of patients treated for multiple myeloma using a new algorithm in the French national health insurance database (SNDS): Results from the MYLORD study. PLOS One, 2025;20(5). PLOS One can be contacted at: Public Library Science, 1160 Battery Street, Ste 100, San Francisco, CA 94111, USA. (Public Library of Science - www.plos.org; PLOS One - www.plosone.org)

The news correspondents report that additional information may be obtained from Fanny Raguideau, HEVA, Lyon, France. Additional authors for this research include Cyrille Touzeau, Helene Denis, Ludovic Lamarsalle, Caroline Guilmet, Matthieu Javelot, Marie Pierres and Aurore Perrot.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1371/journal.pone.0322474. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher’s contact information for the journal PLOS One is: Public Library Science, 1160 Battery Street, Ste 100, San Francisco, CA 94111, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)